MDHearing Neo XS vs ReSound OMNIA miniRIE

The MDHearing Neo XS is a budget OTC hearing aid featuring an invisible-in-ear design, priced at $397. In our lab testing, it earned a C grade with a SoundScore of 2.9/5, ranking #63 of 65 devices in the OTC hearing aid category. This device presents a mixed performance profile. Its standout strength is excellent feedback handling at 5.0/5, scoring 0.46 points above the category average—meaning users should experience minimal whistling or squealing during everyday use. Own-voice comfort is also solid at 3.2/5, sitting 0.69 points above average, which suggests the device manages occlusion reasonably well for its invisible design. However, speech clarity is a significant weakness. Speech in quiet scored just 1.0/5, falling 1.77 points below the category average, while speech in noise scored 1.0/5, sitting 0.48 points below average. Music streaming scored 0.0/5, coming in 1.92 points below average—indicating this device is not suitable for audio entertainment. These low absolute scores mean users may struggle to achieve meaningful speech benefit in our standardized test conditions. The invisible-in-ear form factor and rechargeable batteries offer convenience, but buyers should weigh this against the limited speech performance. Several competitors in the same price range—including the Elehear Beyond (4.34/5) and Apple AirPods Pro 2 (4.04/5)—deliver substantially better sound quality. The Neo XS may appeal to those prioritizing discretion and feedback-free wear over speech clarity, but most users seeking improved communication would benefit from exploring higher-performing alternatives.

The ReSound OMNIA miniRIE is a premium prescription behind-the-ear hearing aid released in 2022, priced at $4,764. In our lab testing, it earned a SoundScore of 4.0/5 (A grade), ranking #26 of 39 prescription hearing aids tested. This device demonstrates solid speech clarity in quiet environments, scoring 3.7/5—0.26 points above the category average. Own-voice comfort also measures slightly above average at 2.9/5. However, the OMNIA miniRIE struggles in challenging listening situations, with speech-in-noise performance scoring just 1.0/5, which is 1.11 points below the category average and low in absolute terms. This represents a significant limitation for users who frequently encounter noisy environments like restaurants or social gatherings. Feedback handling is strong in absolute terms at 4.1/5, though this falls 0.62 points below the prescription hearing aid category average of 4.72/5. Music streaming performance is mixed at 2.7/5, essentially matching the category average. The device offers modern connectivity features including iPhone and Android streaming, hands-free calling, and rechargeable batteries. While the OMNIA miniRIE has earned Expert's Choice Awards in 2023 and 2024, consumers in this premium price tier should note that several competitors—including the Phonak Sphere Infinio and Oticon Intent—achieve higher overall scores. This hearing aid may be best suited for individuals who prioritize performance in quieter settings and value ReSound's ecosystem, but those needing robust noise management should explore alternatives.